Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRELysin in Healthy and VRE-Colonized Adults
NCT05715619Phase 2Suspended
- Sponsor
- Intralytix, Inc.
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Single Strain Products, Multi-strain Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in vancomycin-resistant enterococcal colonization comparing Placebo with VRELysin™ (2 arms). Primary endpoint: Number and Severity of Solicited and Unsolicited Adverse Reactions at 180 days. Started Oct 2023; status: suspended.
02
Drugs
VRELysin
03
Conditions
vancomycin-resistant enterococcal colonization
Beyond the preview
Go deeper on NCT05715619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05715619.